Virginia’s 2025 Ban on Noncompete Agreements for Overtime-Eligible Employees: What You Need to Know

Apr 14, 2025 | News, State-Specific Regulations

A big shift is coming to Virginia employment law—and employers need to be ready. Beginning July 1, 2025, noncompete agreements will be prohibited for all employees eligible for overtime pay, regardless of how much they earn. If your business currently uses noncompetes...

Massachusetts Board of Pharmacy Reiterates Stance on 503A Retail Pharmacies

Apr 10, 2025 | News, State-Specific Regulations

On April 3, 2025, the Massachusetts Board of Registration in Pharmacy issued a memorandum that directly affects 503A retail pharmacies that purchase compounded preparations from 503B outsourcing facilities with the intent to sell those compounded preparations to...

How Tariffs Could Impact The Injectable Supply Chain — And What You Can Do About It

Apr 8, 2025 | News

The U.S. aesthetic industry, particularly the market for botulinum toxins and dermal fillers, is facing an emerging threat: international tariffs. The federal government’s ongoing trade tensions and the possibility of new tariffs on aesthetic injectables could...

Texas Med Spas & Wellness Clinics: Five Proposed Bills That Could Impact Your Business

Apr 5, 2025 | News, State-Specific Regulations

The Texas Legislature is currently reviewing several bills that could significantly affect the operation of medical spas and wellness clinics across the state. While the intent may be to protect patient safety, these proposals introduce burdensome restrictions that...

Med Spa Shut Down Over Counterfeit Injectables: What Med Spas Need to Know

Apr 3, 2025 | News

An Ohio medical spa is facing serious consequences after state regulators discovered it was using unapproved and potentially counterfeit injectables. This latest enforcement action highlights the ongoing crackdown on med spas that fail to follow proper drug-sourcing...

Eli Lilly Sues Compounders Over Unauthorized Copies of Weight-Loss Drugs

Apr 2, 2025 | News

Eli Lilly has taken another firm legal stance against compounding pharmacies producing unapproved versions of its blockbuster weight-loss and diabetes drugs, Mounjaro and Zepbound (tirzepatide). On April 1, 2025, the pharmaceutical giant filed lawsuits against two...